NLCIPS: Non-small cell lung cancer immunotherapy prognosis score

Abstract

Introduction: Currently in China, many immune checkpoint inhibitors (ICIs) have been approved for the treatment of non-small cell lung cancer (NSCLC). Some patients can not benefit from ICIs, and approximately 50% of patients have immunotherapy-related toxicity. Therefore, it is necessary to monitor carefully the selection of immunotherapy population using biomarkers to maximize the benefit of patients with NSCLC. Methods: A prospective analysis was performed on patients with advanced NSCLC who were treated with ICIS at our hospital from March 2018 to June 2019, up to the follow-up deadline of December 31, 2019. The primary end points were overall survival (OS) and progression-free survival (PFS), and the secondary end points were objective response rate and disease control rate. A lasso regression was used for the univariate analysis, and Cox regression analysis was used for the multivariate analysis. An efficacy prediction line chart was developed. Results: A total of 63 patients were included in the study. The median PFS was 7.0 months (95% CI, 5.0–11.0) and did not reach the median OS. According to the lasso regression, significant univariate factors were smoking index, PD-ligand 1 expression, and neutrophil to lymphocyte ratio (NLR). According to the multivariate analysis, the Cox proportional hazards model showed that smoking index and NLR are independent predictors of PFS in immunotherapy. A model comprised of independent predictors was developed based on a multivariate logical analysis of the main cohort—non-small cell lung cancer immunotherapy prognosis score. This model is shown as a nomogram with a C-index of 0.801 (95% CI, 0.744, 0.858), which has high prediction accuracy. Conclusion: This predictive model, including NLR and smoking index, can achieve a 1-year PFS in immunotherapy of patients. PD-1 inhibitors have been demonstrated to be effective and safe in the clinical treatment of patients with NSCLC.